Evidence map›Paper›PMID 33340620›Full record

ReviewAdvanced drug delivery reviews2021

Non-viral COVID-19 vaccine delivery systems.

Kyung Soo Park, Xiaoqi Sun, Marisa E Aikins, James J Moon

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 215 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kyung Soo ParkDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Xiaoqi SunBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
Marisa E AikinsBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
James J MoonDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: moonjj@med.umich.edu.
University of Michigan–Ann Arbor · US

Funding

Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Environmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6M
Novel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5M
Elicitation of mucosal immune responses against HIVR01AI127070 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2020
$2.3M
Nanomaterials for eliciting anti-tumor T-cells-Diversity SupplementR01CA210273 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2017 to 2021
$2.2M
NCI NIH HHS R01 CA210273NCI NIH HHS U01 CA210152NIAID NIH HHS R01 AI127070NIDCR NIH HHS T32 DE007057NIDDK NIH HHS R01 DK125087
6 · The paper itself

Abstract

The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.

Indexed as

AnimalsCOVID-19COVID-19 VaccinesDrug Delivery SystemsHumansVaccines, DNAVaccines, SyntheticCOVID-19 VaccinesVaccines, DNAVaccines, Synthetic

Identifiers

PMID33340620
PMCPMC7744276
OpenAlexW3113148639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.